Page 89 - DUOKOPT BIBLIOBOOK

EFFICACY

IOP-Lowering Effects of Fixed-Combination Drugs

Relative (%) (1.23) 30.95 - - (2.17) 26.99 (1.20) 40.70 - - (0.99) 33.69 (1.19) 30.55 (1.25) 27.12 (0.67) 34.51 (1.75) 25.59 (1.97) 31.54 (1.85) 27.31 (1.53) 36.38 (1.16) 30.99 (0.99) 30.97 (0.88) 34.63 (0.79) 34.25 (2.63) 35.90 (2.63) 35.20 - (0.83) 26.85 (3.19) 21.7 (1.36) 34.40 - (1.55) 34.30 (1.57) 32.90 (1.14) 28.57 (0.57) 34.29 (1.95) 23.58 (1.23) 20.86 (2.16) 32.16

(SE) Hg) (0.31) (0.44)
Diurnal Absolute (mm (0.42) 8.65 - - (0.49) 6.10 10.50 (0.36) 6.80 (0.30) 7.49 (0.28) 9.40 (0.33) 8.40 (0.30) 6.40 (0.18) 9.11 (0.43) 6.29 8.20(0.51) 6.80(0.46) 10.43 (0.28) 7.50 (0.24) 7.63 (0.22) 8.37 (0.20) 8.70 (0.68) 9.26 (0.68) 9.20 - (0.19) 6.17 (0.87) 4.50 (0.34) 8.60 - (0.35) 7.80 (0.33) 7.40 (0.29) 7.20 (0.14) 8.40 (0.48) 5.80 (0.30) 5.10 (0.49) 7.30

Relative (%) (1.22) 28.20 - - (1.18) 18.19 - - - (1.17) 32.97 (1.39) 29.03 (1.72) 23.89 - (1.88) 25.41 (2.53) 30.88 (2.36) 25.42 (1.54) 33.82 (1.81) 26.87 (1.13) 29.20 (0.92) 32.17 (0.81) 33.20 (2.36) 33.90 (2.37) 34.40 (2.33) 38.60 (0.92) 22.84 (2.79) 15.59 (2.11) 30.30 - (1.79) 33.90 (1.66) 32.80 (1.57) 23.18 (0.73) 33.05 (2.23) 21.12 (1.38) 14.68 (1.66) 25.47

(SE) Hg)
Lowest Absolute (mm (0.42) (0.25) (0.32) (0.39) (0.39) 6.20(0.46) (0.65) (0.57) (0.42) (0.41) (0.26) (0.21) (0.20) (0.63) (0.63) (0.94) (0.20) (0.52) (0.49) (0.38) (0.37) (0.37) (0.17) (0.56) (0.30) (0.35)
arm. 8.00 - - 3.90 - - - 9.10 8.10 5.40 - 8.00 6.10 9.20 6.10 6.90 7.40 8.20 8.34 8.70 8.50 4.98 2.90 7.00 - 7.50 7.20 5.40 7.70 5.30 3.20 5.40
study (1.23) (3.22) (2.16) (0.74) (1.37) (1.41) (1.29) (2.40) (2.51) (2.58) (1.52) (1.47) (0.86) (0.85) (0.77) (2.74) (2.73) (0.73) (1.58) (1.66) (1.60) (1.46) (1.43) (1.30) (0.62) (2.31) (1.17) (1.32)

per Relative (%) 33.70 26.17 25.10 38.17 - - - 33.33 32.36 29.60 - 26.12 30.86 29.44 37.42 38.11 33.20 37.15 35.00 37.80 36.10 - 32.15 26.84 39.34 27.08 34.70 33.20 35.06 37.07 24.48 25.68 37.69
decrease (SE) Hg) (0.41) (0.82) (0.54) (0.18) (0.39) (0.39) (0.32) (0.59) (0.46) (0.39) (0.22) (0.22) (0.20) (0.68) (0.68) (0.17) (0.37) (0.45) (0.38) (0.35) (0.33) (0.35) (0.16) (0.56) (0.30) (0.35)

IOP Highest Absolute (mm 9.30 6.70 6.30 9.50 - - - 9.60 8.90 7.40 - 6.40 8.30(0.68) 7.30(0.64) 11.30 10.10 8.60 9.40 9.10 10.10 9.60 - 7.49 6.20 10.70 6.50 8.20 7.80 9.50 9.60 5.90 6.60 10.10
lowest 22 18, 22 18, 12 10, 12 10,

and points after 9 10 8 8 9 14, 10, 20 19 9 11 14, 10, 10 8, 6, 12 10, 8, 6,
highest Time (hours dosing) 2 0, 2 2 6, 3, 0, 6, 2, 6, 2, 0, 6, 2, 0, 8 4, 0, 8 4, 0, 6, 2, 0, 8 4, 0, 7 3, 0, 8 4, 0, 8 2, 0, 8 2, 0, 6, 3, 8 2, 0, 8 2, 0, 16, 12, 7 2, 0, 14, 12, 3 7, 2, 0, 7, 3, 6, 2, 4 8 4, 0, 8 4, 0, 6, 2, 8 2, 0, 4, 2, 0, 6, 2, 0, 4, 2, 0,

the
curve, of measurement (2) Curve (1) (1) (8) Curve (6) Curve (4) Curve (4) Curve (3) Curve (3) Curve (4) Curve (3) Curve (3) Curve (3) Curve (3) Curve (3) Curve (6) Curve (3) Curve (3) Curve (3) Curve (3) Curve (3) Curve (1) (4) Curve (4) Curve (6) Curve (1) (3) Curve (3) Curve (6) Curve (3) Curve (7) Curve (8) Curve (12) Curve

diurnal Type IOP Single Single IOP IOP IOP IOP IOP IOP IOP IOP IOP IOP IOP IOP IOP IOP IOP IOP IOP IOP Single IOP IOP IOP Single IOP IOP IOP IOP IOP IOP IOP

mean of

for point measurement
IOP End (weeks) 4 4 6 4 6 4 4 13 13 8 4 4 6 8 6 8 6 6 12 6 6 4 6 6 8 4 4 4 8 6 8 6 6
in
reductions timolol timolol timolol timolol timolol timolol timolol timolol timolol timolol timolol timolol timolol timolol timolol timolol timolol timolol timolol timolol timolol timolol timolol timolol timolol timolol timolol timolol timolol timolol timolol timolol timolol

relative Dorzolamide/0.5% Dorzolamide/0.5% Dorzolamide/0.5% Dorzolamide/0.5% Dorzolamide/0.5% Dorzolamide/0.5% Dorzolamide/0.5% Latanoprost/0.5% Dorzolamide/0.5% Dorzolamide/0.5% Latanoprost/0.5% Latanoprost/0.5% Latanoprost/0.5% Dorzolamide/0.5% Travoprost/0.5% Latanoprost/0.5% Travoprost/0.5% Travoprost/0.5% Latanoprost/0.5% Travoprost/0.5% Travoprost/0.5% Latanoprost/0.5% Brimonidine/0.5% Dorzolamide/0.5% Latanoprost/0.5% D

and Medication 2.0% 2.0% 2.0% 2.0% 2.0% 2.0% 2.0% 0.005% 2.0% 2.0% 0.005% 0.005% 0.005% 2.0% 0.004% 0.005% 0.004% 0.004% 0.005% 0.004% 0.004% 0.005% 0.2% 2.0% 0.005% 2.0% 0.2% 2.0% 2.0% 0.03% 2.0% 2.0% 2.0%
Absolute

3. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36]
Table Trial 199810/01 200303/01 200304/01 200307/01 200402/01 200402/02 200405/01 200407/01 200409/01 200410/01 200505/01 200507/01 200507/02 200508/01 200510/01 200601/01 200603/01 200603/02 200609/01 200609/02 200611/01 200702/01 200704/01 200801/01 200804/01 200808/01 200808/02 200810/01

PLOS ONE | www.plosone.org 7 September 2012 | Volume 7 | Issue 9 | e45079 89